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Aim: The Danish National Chronic Myeloid Neoplasia Registry (DCMR) is a population-based 
clinical quality database, introduced to evaluate diagnosis and treatment of patients with chronic 
myeloid malignancies. The aim is to monitor the clinical quality at the national, regional, and 
hospital departmental levels and serve as a platform for research.
Study population: The DCMR has nationwide coverage and contains information on patients 
diagnosed at hematology departments from January 2010 onward, including patients with 
essential thrombocythemia, polycythemia vera, myelofibrosis, unclassifiable myeloproliferative 
neoplasms, chronic myelomonocytic leukemia, and chronic myeloid leukemia.
Main variables: Data are collected using standardized registration forms (so far up to four 
forms per patient), which are consecutively filled out online at time of diagnosis, after 2-year and 
5-year follow-ups, and at end of follow-up. The forms include variables that describe clinical/
paraclinical assessments, treatment, disease progression, and survival – disease-specific variables 
– as well as variables that are identical for all chronic myeloid malignancies.
Descriptive data: By the end of 2014, the DCMR contained data on 2,690 patients with an 
inclusion rate of ∼500 patients each year. Since the registry was established, annual reports 
have shown consistently high national coverage and data completeness, $90% and $88%, 
respectively.
Conclusion: The DCMR is a national database used for monitoring the quality of patient care 
in patients with chronic myeloid malignancies, but until validation has been conducted, the 
data must be used with caution. However, the DCMR is a valuable data source accessible to 
clinicians and researchers.
Keywords: myeloproliferative disorders, database, treatment, health care quality assurance, 
outcome assessment, epidemiology, research
Introduction
The Danish National Chronic Myeloid Neoplasia Registry (DCMR) was established 
on January 1, 2010, to monitor the clinical quality of diagnosis and treatment in 
patients with chronic myeloid malignancies. This population-based clinical quality 
database with nationwide coverage contains information on patients with essential 
thrombocythemia, polycythemia vera, myelofibrosis, unclassifiable myeloprolifera-
tive neoplasms, chronic myelomonocytic leukemia, and chronic myeloid leukemia. 
The DCMR is part of the Danish Common Hematological Database established by 
the Danish Society of Hematology, to evaluate patients with various hematological 
malignancies and to ensure the quality of diagnostic evaluation, treatment, and patient 
care at the national level, as well as in each hematology department.
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Aim of the database
The aim of the DCMR is to collect information on patients 
with different subtypes of chronic myeloid malignancies, to 
gain insight into disease epidemiology, and to characterize 
patients by clinical and paraclinical evaluation at predefined 
intervals throughout the course of the cancers. The DCMR 
enables nationwide monitoring of the quality of diagnosis 
and treatment in patients with chronic myeloid malignan-
cies in Denmark. As with all government-approved clinical 
quality databases, a continuous aim is also to ensure cover-
age .90% and registration completeness .80% each year, 
at the national, regional, and hospital departmental levels. 
The database can also be used to compare different patient- 
and treatment-related outcomes between departments. The 
DCMR serves as a quality database as well as a research 
database.
Study population
Danish citizens with chronic myeloid malignancies, referred 
to hematology departments for evaluation since January 1, 
2010, are eligible for registration in the DCMR. All nine 
hematology departments in Denmark are obliged to collect 
and enter data. Patients diagnosed or treated outside Denmark 
are included only if their treatment is continued in Denmark. 
The patients must fulfill the current World Health Organiza-
tion classification criteria for essential thrombocythemia, 
polycythemia vera, myelofibrosis, unclassifiable myelopro-
liferative neoplasms, chronic myelomonocytic leukemia, or 
chronic myeloid leukemia to be included in the DCMR.1
The Danish health care system provides free health care 
to all 5.5 million inhabitants,2 which enables nationwide 
coverage of the DCMR. In 2009, the Danish Health and 
Medicines Authority introduced the hematological cancer 
care packages, as part of the national initiative termed 
The National Integrated Cancer Pathways.3 The regulation 
included guidelines for Danish patients with hemato-
logical cancer, implying that all patients with a suspected 
hematological cancer must be evaluated at a hematology 
department. This ensures that data on virtually all in- and 
outpatients with chronic myeloid malignancies are included 
in the DCMR, and data are collected on ∼500 new patients 
each year.
Registration system and variables
Registration system
The Web-based registration system for entering data into the 
DCMR (as well as all other hematological registries) is based 
on a reporting tool, developed using SAS Institute software 
version 9.2 (SAS Institute Inc, Cary, NC, USA). The entered 
data are securely stored electronically. The online registra-
tion system is easily accessible from every department in 
Denmark, and physicians do not need patients’ consent when 
entering data. Data are collected from patients’ pathology and 
laboratory reports, medical files, and assessments by the con-
sulting hematologists. Trained health care professionals enter 
data on all  eligible patients into the system manually, using 
standardized registration forms. Instructions for entering 
data are available online to ensure a homogeneous national 
registration. Validation rules, including field and cross-vali-
dation, restrict what can be entered, and each variable must 
be answered before the registration forms can be submitted, 
thus optimizing the completeness of the registration.
Registration forms and main variables
For each patient, data collected on up to four registration 
forms entered at predefined intervals are included in the 
DCMR so far. The registration algorithm for the DCMR is 
shown in Figure 1. The different forms contain detailed infor-
mation on administrative and clinical data. Main variables 
are shown in Table 1. At time of diagnosis, the department 
that verifies the diagnosis enters the first registration form 
(Registration Form), which must be entered within 6 months 
after diagnosis. The form contains information about the 
diagnosis and date of diagnosis, symptoms, and paraclinical, 
cytogenetic, and molecular profiles. The second registration 
form (the 2-Year Registration Form), entered 2 years after 
diagnosis, includes information on disease progression and 
the treatment initiated within the first 2 years. The third 
registration form (the 5-Year Registration Form), submitted 
5 years after diagnosis, was introduced in 2015 and includes 
variables related to disease progression, cytogenetic and 
molecular assessment, and treatment. At end of follow-
up (eg, death or progression to acute leukemia), a fourth 
registration form (the Follow-up Form), which includes 
information on date of last follow-up and vital status, must 
be completed.
Follow-up
validity and coverage
The Danish Civil Registration System (CRS),4,5 with unique 
personal identification numbers that track each citizen 
nationwide, allows merging of data between different 
Danish  registries,6,7 including the DCMR and the Danish 
National Patient Registry (DNPR). The DNPR contains 
information on all in- and outpatient hospital visits in 
Denmark,8,9 and the coding procedures for hematological 
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diseases show high  validity.10,11 Because vital status and 
date of death are  available for all citizens in the CRS, 
data from the DCMR are merged with the CRS using an 
administrative algorithm. Entering data on all patients in the 
database is mandatory and automatic cross-merging with 
the DNPR provides departments with follow-up lists (names 
and identification numbers), including a data list of correctly 
entered patients as well as patients whose data have not 
yet been correctly entered in the DCMR. This is done by 
extracting codes from the DNPR that correspond to chronic 
myeloid malignancies at any hematology department in 
Denmark. As a result, no patients are lost to follow-up in 
the DCMR. Furthermore, the registration system allows 
departments to change incorrectly entered data manually, 
resulting in subsequent data correction within the database, 
eg, if an incorrect diagnosis has been entered for a patient. 
The cross-merging of data between the DNPR and DCMR 
enables each department to maintain high data coverage, 
and it is an effective attempt to increase the validity of 
the DCMR.
Annual reports
The steering committee of the Danish National Chronic Myel-
oid Neoplasia Study Group (DCMSG) annually publishes 
an online report in Danish based on data from the DCMR. 
The report includes eight quality indicators that encompass 
database coverage, mortality, number of patients included 
in  protocols, and cytogenetic and molecular  biological 
assessment calculated for patients included within the past 
year. Data completeness (patients with submitted 2-Year 
Registration Forms) and long-term follow-up with  survival 
estimates are also included, using data from preceding years. 
In addition, data are cross-merged with the DNPR to calculate 
coverage and completeness each year. The indicators assess 
quality of the database (coverage and completeness) as well 
as the quality of patient-related outcomes such as survival 
rates. The indicators are reported yearly at the departmen-
tal, regional, and national levels. National  quality indicator 
results from the previous 3 years are shown in Table 2. In total, 
2,690 patients were included in the DCMR from 2010 to 2014 
(essential thrombocythemia =744, polycythemia vera =729, 
myelofibrosis =374, myeloproliferative neoplasms =370, 
chronic myelomonocytic leukemia =196, chronic myeloid 
leukemia =277), and consistently high national coverage 
($90%) and completeness ($88%) have been observed since 
the registry was established.12
Administrative issues and funding
The DCMR is approved as a clinical quality database by the 
Danish authorities – the National Board of Health and the 
Danish Data Protection Agency. The Danish Common 
Hematological Database, including the DCMR, is part of 
the Danish Multidisciplinary Cancer Groups, which receive 
public financial support from the Danish regions. The 
Registry Support Centre of Epidemiology and Biostatistics 
(East) ensures administration of the database, support, and 
maintenance of the operating system and provides  statistical 
analyses and epidemiological assistance for the annual 
reports, published in collaboration with the DCMSG. The 
academic and professional responsibility for maintenance 
and use of the DCMR lies within the DCMSG, (includ-
ing the development and optimization of the database by 
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Figure 1 The Danish National Chronic Myeloid Neoplasia Registry algorithm.
Note: Data are entered at predefined intervals for each patient (at time of diagnosis, after 2-year and 5-year follow-ups, and at end of follow-up).
Abbreviations: CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CRS, The Danish Civil Registration System; DCMR, The Danish National 
Chronic Myeloid Neoplasia Registry; DNPR, The Danish National Patient Registry; ET, essential thrombocythemia; MF, myelofibrosis; MPN-U, unclassifiable myeloproliferative 
neoplasm; Pv, polycythemia vera.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
27
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
570
Bak et al
Table 1 Main variables recorded on standardized online registration forms in the Danish National Chronic Myeloid Neoplasia Registry
Registration form  
(time of registration)
Main variables
Nondisease-specific variables Disease-specific variables
Registration form  
(submitted at time of  
diagnosis)
Name and civil registration number ET, Pv, MF, MPN-U
Diagnosis according to wHO 2008/iCD-10  Prior other cancer (solid/nonsolid)
Date of diagnosis  inherited MPN predisposition
Prior hematological disease (.3 months’ duration)  Prior thrombosis (specified, if present)
B-symptoms: weight loss, night sweat, and itching  Bleedings
Spleen enlargement (if yes, then clinical or image  
verified)
 Musculoskeletal symptoms (related to MPN)
 Microvascular symptoms (specified, if present)
 Cardiovascular risk factors
 Cytogenetic and molecular biological assessments:
  JAK2v617F, JAK2 exon 12, MPL, CALRa, ASXL1a
  if present, JAK2v617F, MPL, and CALR allele burdena
CML
 BCR-ABL1 expression level (% iS)a
 Chromosomal abnormalities, besides t(9;22)
 Disease phase: chronic, accelerated, blast crisis
CMML
 Cytogenetic and molecular biological assessment (r-iPSS)
Laboratory values
Biological material for a biobank
2-Year Registration Form  
(submitted 2 years after 
diagnosis)
Date of registration ET, Pv, MF, MPN-U
Spleen enlargement or progressiona  vascular events since diagnosisa (specified if present)
Cytogenetic and molecular biological assessment  if present, JAK2v617F, MPL, and CALR allele burdena
Treatment (within the first 2 years) CML
Participation in clinical research protocol  Monitoring with qPCR or dPCR
Progression of disease  BCR-ABL1 expression level (% iS)a
 Chromosomal abnormalities besides t(9;22)a
 Mutation status in patients with treatment resistancea
 Treatment responsea
 vascular events since diagnosisa (specified if present)
5-Year Registration Form  
(submitted 5 years after 
diagnosis)
Transplantation: date and type of transplantation ET, Pv, MF, MPN-U
Date of registration  vascular events since diagnosisa (specified if present)
Spleen enlargement or progressiona  if present, JAK2v617F, MPL, and CALR allele burdena
Cytogenetic and molecular biological assessment CML
Treatment  Monitoring with qPCR or dPCR
Participation in clinical research protocol  BCR-ABL1 expression level (% iS)a
Progression of disease  Chromosomal abnormalities besides t(9;22)a
Transplantation: date and type of transplantation  Mutation status in patients with treatment resistancea
 Treatment responsea
 vascular events since diagnosisa (specified if present)
Follow-up Form  
(submitted at end of 
 follow-up)
vital status
Date of follow-up or date of death
Place of death
Note: aintroduced in 2015.
Abbreviations: ASXL1, the additional sex combs-like gene; BCR-ABL1, BCR-ABL1 fusion gene (Philadelphia chromosome); CALR, calreticulin; CML, chronic myeloid 
leukemia; CMML, chronic myelomonocytic leukemia; dPCR, digital polymerase chain reaction; ET, essential thrombocythemia; ICD, International Classification of Diseases; 
IS, International Scale; JAK2V617F, janus kinase2V617F mutation;  MF, myelofibrosis; MPL, myeloproliferative leukemia protein (thrombopoietin receptor); MPN, myeloproliferative 
neoplasm; MPN-U, unclassifiable myeloproliferative neoplasms; PV, polycythemia vera; qPCR, quantitative polymerase chain reaction; WHO, World Health Organization.
improving registration forms, introducing new variables, 
and surveying variables). Access to data from the DCMR 
can be obtained by applying to the Registry Support Cen-
tre of Epidemiology and Biostatistics, but researchers can 
only be granted access after approval from the Danish 
authorities.
Conclusion
Hematology departments in Denmark enter data into the 
DCMR through the online registration system, to generate 
information on a nationwide cohort of patients with chronic 
myeloid malignancies. The DCMR ensures that departments 
have the possibility of monitoring diagnosis and  treatment 
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in patients at predefined intervals and comparing  quality 
 indicator results with national levels yearly. Recent  quality 
studies of Danish hematological databases, the  Danish 
National Lymphoma Registry, and the Danish National 
Acute  Leukemia Registry, which use the same reporting 
tool and trained health care professionals for entering data, 
show high data quality.13,14 However, generated data in the 
DCMR must be used with caution, until a validity study 
has been undertaken and data quality has been assessed. 
The DCMR, a population-based clinical quality database 
(with high coverage), represents a unique data source for 
physicians to scrutinize and monitor the clinical quality of 
diagnosis and treatment of Danish patients with chronic 
myeloid malignancies. In addition, the database addresses 
research-related questions, generating valuable information 
of interest to clinicians and researchers, as well as patients 
and politicians.
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Table 2 Quality indicators in the Danish National Chronic 
Myeloid Neoplasia Registry
National quality indicators in the DCMR (%)
Year 2014 2013 2012
Database-related indicators (quality of the database)
 Database coveragea 90 97 98
  Data completeness (submitted 
2-Year Registration Forms)
88 96 99
Patient-related indicators (quality of patient-related outcomes)
 30-day mortality 0.5 0.5 0.6
 180-day mortality 3.7 3.9 4.5
  Cytogenetic or molecular biological 
diagnostics performed
97 97 98
  Patients included in a clinical protocol 14 2 3
Year of registration 2013–2014b 2011–2012b
 1-year survival 92 92 –
2011–2014b – –
 3-year survival 80 – –
Notes: National quality indicator results (calculated for the years 2012–2014). Each 
indicator is calculated as percentage of patients that meet the indicator criteria. 
aCoverage of the DCMR, is calculated annually as patients within the registry, divided 
by all patients with chronic myeloid malignancies in hematology departments in 
Denmark. bPatients with registration in the database over the years are pooled. 
Abbreviation: DCMR, Danish National Chronic Myeloid Neoplasia Registry.
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